February 2, 2016February 3, 2016

FDA Approves IND Application for Multidrug-Resistant Bacterial Infections

Bronchiectasis, COPD, Cystic Fibrosis, Emphysema, News, Pneumonia

Matinas BioPharma Holdings recently announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application, and the company can now begin a Phase 1 clinical trial to ... Read more

January 15, 2016

Matinas BioPharma Fills IND Application for Antibacterial Drug Development

Bronchiectasis, COPD, Cystic Fibrosis, News

Matinas BioPharma of Bedminster, N.J., filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the development of its antibacterial drug MAT2501 for the ... Read more